Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1991 participants.
Also called NCT02730377
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,991 participants
- Sponsor
- Registry
-
NCT02730377 -
2015-002417-29
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Colombia, India, Latvia, Lebanon, Puerto Rico, Russia, Serbia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02730377. Randomized; no masking; primary purpose treatment. Start 2016-03-28 (actual); primary completion 2019-08-05 (actual). Results posted on 2020-07-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
- Acronym
- LIRA-PRIME
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- alpha-glucosidase inhibitors
- Intervention (Drug)
- DPP-4 inhibitors
- Intervention (Drug)
- meglitinides
- Intervention (Drug)
- SGLT-2 inhibitors
- Intervention (Drug)
- sulphonylurea
- Intervention (Drug)
- thiazolidinediones
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02730377- Content hash
65ac89cedeb877fe341d31a532e9700eebe98e3764c9d7494cf574cff4f10bab